|
1
|
Takeuchi A, Yamamoto N, Hayashi K,
Matsubara H, Miwa S, Igarashi K and Tsuchiya H: Joint-preservation
surgery for pediatric osteosarcoma of the knee joint. Cancer
Metastasis Rev. 38:709–722. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lilienthal I and Herold N: Targeting
molecular mechanisms underlying treatment efficacy and resistance
in osteosarcoma: A review of current and future strategies. Int J
Mol Sci. 21:68852020. View Article : Google Scholar :
|
|
3
|
Hattinger CM, Patrizio MP, Magagnoli F,
Luppi S and Serra M: An update on emerging drugs in osteosarcoma:
Towards tailored therapies? Expert Opin Emerg Drugs. 24:153–171.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ando K, Heymann MF, Stresing V, Mori K,
Rédini F and Heymann D: Current therapeutic strategies and novel
approaches in osteosarcoma. Cancers. 5:591–616. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li B, Zhou P, Xu K, Chen T, Jiao J, Wei H,
Yang X, Xu W, Wan W and Xiao J: Metformin induces cell cycle
arrest, apoptosis and autophagy through ROS/JNK signaling pathway
in human osteosarcoma. Int J Biol Sci. 16:74–84. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ferrari S and Serra M: An update on
chemotherapy for osteosarcoma. Expert Opin Pharmacother.
16:2727–2736. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Whelan JS, Jinks RC, McTiernan A, Sydes
MR, Hook JM, Trani L, Uscinska B, Bramwell V, Lewis IJ, Nooij MA,
et al: Survival from high-grade localised extremity osteosarcoma:
Combined results and prognostic factors from three European
Osteosarcoma Intergroup randomised controlled trials. Ann Oncol.
23:1607–1616. 2012. View Article : Google Scholar :
|
|
8
|
Li S, Sun W, Wang H, Zuo D, Hua Y and Cai
Z: Research progress on the multidrug resistance mechanisms of
osteosarcoma chemotherapy and reversal. Tumour Biol. 36:1329–1338.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Anderson ME: Update on survival in
osteosarcoma. Orthop Clin North Am. 47:283–292. 2016. View Article : Google Scholar
|
|
10
|
Chen LB: Mitochondrial membrane potential
in living cells. Annu Rev Cell Biol. 4:155–181. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pan Y, Wang Z, Shao D, Zheng H, Chen Y,
Zheng X, Zhang M, Li J, Li F and Chen L: CTAB induced mitochondrial
apoptosis by activating the AMPK-p53 pathway in hepatocarcinoma
cells. Toxicol Res. 4:1359–1365. 2015. View Article : Google Scholar
|
|
12
|
Umpleby HC and Williamson RC: The efficacy
of agents employed to prevent anastomotic recurrence in colorectal
carcinoma. Ann R Coll Surg Engl. 66:192–194. 1984.PubMed/NCBI
|
|
13
|
Sonişik M, Korkmaz A, Besim H, Karayalçin
K and Hamamci O: Efficacy of cetrimide-chlorhexidine combination in
surgery for hydatid cyst. Br J Surg. 85:12771998. View Article : Google Scholar
|
|
14
|
Singh R, Letai A and Sarosiek K:
Regulation of apoptosis in health and disease: The balancing act of
BCL-2 family proteins. Nat Rev Mol Cell Biol. 20:175–193. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kagan VE, Tyurin VA, Jiang J, Tyurina YY,
Ritov VB, Amoscato AA, Osipov AN, Belikova NA, Kapralov AA, Kini V,
et al: Cytochrome c acts as a cardiolipin oxygenase required for
release of proapoptotic factors. Nat Chem Biol. 1:223–232. 2005.
View Article : Google Scholar
|
|
16
|
Hennessy BT, Smith DL, Ram PT, Lu Y and
Mills GB: Exploiting the PI3K/AKT pathway for cancer drug
discovery. Nat Rev Drug Discov. 4:988–1004. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Delaloge S and DeForceville L: Targeting
PI3K/AKT pathway in triple-negative breast cancer. Lancet Oncol.
18:1293–1294. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jiang F, Shi Y, Li GJ and Zhou F: A
meta-analysis of limb-salvage versus amputation in the treatment of
patients with Enneking‡U pathologic fracture osteosarcoma. Indian J
Cancer. 51(Suppl 2): e21–e24. 2015.
|
|
19
|
Yang C, Tian Y, Zhao F, Chen Z, Su P, Li Y
and Qian A: Bone microenvironment and osteosarcoma metastasis. Int
J Mol Sci. 21:69852020. View Article : Google Scholar :
|
|
20
|
Chindamo G, Sapino S, Peira E, Chirio D,
Gonzalez MC and Gallarate M: Bone diseases: Current approach and
future perspectives in drug delivery systems for bone targeted
therapeutics. Nanomaterials (Basel). 10:8752020. View Article : Google Scholar
|
|
21
|
Vos HI, Coenen MJ, Guchelaar HJ and Te Loo
DM: The role of pharmacogenetics in the treatment of osteosarcoma.
Drug Discov Today. 21:1775–1786. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fu Y, Yu W, Cai H and Lu A: Forecast of
actin-binding proteins as the oncotarget in osteosarcoma-a review
of mechanism, diagnosis and therapy. Onco Targets Ther.
11:1553–1561. 2018. View Article : Google Scholar :
|
|
23
|
Cui J, Dean D, Hornicek FJ, Chen Z and
Duan Z: The role of extracelluar matrix in osteosarcoma progression
and metastasis. J Exp Clin Cancer Res. 39:1782020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wissing MD, Mendonca J, Kim E, Kim E, Shim
JS, Kaelber NS, Kant H, Hammers H, Commes T, Van Diest PJ, et al:
Identification of cetrimonium bromide and irinotecan as compounds
with synthetic lethality against NDRG1 deficient prostate cancer
cells. Cancer Biol Ther. 14:401–410. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Park K, Chetty U, Scott W and Miller W:
The activity of locally applied cytotoxics to breast cancer cells
in vitro. Ann R Coll Surg Engl. 73:96–99. 1991.PubMed/NCBI
|
|
26
|
Wu TK, Chen CH, Pan YR, Hu CW, Huang FM,
Liu JY and Lee CJ: Cetrimonium bromide inhibits cell migration and
invasion of human hepatic SK-HEP-1 cells through modulating the
canonical and Non-canonical TGF-β signaling pathways. Anticancer
Res. 39:3621–3631. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhou J, Liu T and Wang W: Prognostic
significance of matrix metalloproteinase 9 expression in
osteosarcoma: A meta-analysis of 16 studies. Medicine (Baltimore).
97:e130512018. View Article : Google Scholar
|
|
28
|
Wang G, Zhang T, Sun W, Wang H, Yin F,
Wang Z, Zuo D, Sun M, Zhou Z, Lin B, et al: Arsenic sulfide induces
apoptosis and autophagy through the activation of ROS/JNK and
suppression of Akt/mTOR signaling pathways in osteosarcoma. Free
Radic Biol Med. 106:24–37. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bai L and Wang S: Targeting apoptosis
pathways for new cancer therapeutics. Annu Rev Med. 65:139–155.
2014. View Article : Google Scholar
|
|
30
|
Mohamed MS, Bishr MK, Almutairi FM and Ali
AG: Inhibitors of apoptosis: Clinical implications in cancer.
Apoptosis. 22:1487–1509. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ito E, Yip KW, Katz D, Fonseca SB, Hedley
DW, Chow S, Xu GW, Wood TE, Bastianutto C, Schimmer AD, et al:
Potential use of cetrimonium bromide as an apoptosis-promoting
anticancer agent for head and neck cancer. Mol Pharmacol.
76:969–983. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bock FJ and Tait SWG: Mitochondria as
multifaceted regulators of cell death. Nat Rev Mol Cell Biol.
21:85–100. 2020. View Article : Google Scholar
|
|
33
|
Liu R, Chen Y, Liu G, Li C, Song Y, Cao Z,
Li W, Hu J, Lu C and Liu Y: PI3K/AKT pathway as a key link
modulates the multidrug resistance of cancers. Cell Death Dis.
11:7972020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fattahi S, Amjadi-Moheb F, Tabaripour R,
Ashrafi GH and Akhavan-Niaki H: PI3K/AKT/mTOR signaling in gastric
cancer: Epigenetics and beyond. Life Sci. 262:1185132020.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang H, Jiang H, Zhang H, Liu J, Hu X and
Chen L: Anti-tumor efficacy of phellamurin in osteosarcoma cells:
Involvement of the PI3K/AKT/mTOR pathway. Eur J Pharmacol.
858:1724772019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pan Y, Zhang Y, Chen Q, Tao X, Liu J and
Xiao GG: CTAB enhances chemo-sensitivity through activation of AMPK
signaling cascades in breast cancer. Front Pharmacol. 10:8432019.
View Article : Google Scholar : PubMed/NCBI
|
